Vishwanath, Swarna
Hopper, Ingrid
Cloud, Geoffrey C.
Chong, Trevor T-J
Shah, Raj C.
Donnan, Geoffrey A.
Williamson, Jeff D.
Eaton, Charles B.
Wolfe, Rory
Reid, Christopher M.
Tonkin, Andrew M.
Orchard, Suzanne G.
Fitzgerald, Sharyn
Murray, Anne M.
Woods, Robyn L.
Nelson, Mark R.
Sood, Ajay
Steves, Claire J.
Ryan, Joanne
Funding for this research was provided by:
Monash University
National Health and Medical Research Council Research Leader Fellowship (1135727)
Article History
Received: 21 March 2024
Accepted: 7 May 2024
First Online: 18 May 2024
Declarations
:
: The authors declare no competing interests.
: The ASPREE and ASPREE-XT studies have multiple institutional review board approvals in the US and Australia (). All participants provided written informed consent.
: RCS reports being the site principal investigator or sub-investigator for Alzheimer’s disease clinical trials for which his institution (Rush University Medical Center) is compensated [Amylyx Pharmaceuticals, Inc., Athira Pharma, Inc., Edgewater NEXT, Eli Lilly & Co., Inc., Genentech, Inc.]. TT-JC has received honoraria for lectures from Roche. MRN reports being on a Novartis Lidid Advisory Board in 2020. All other authors report no disclosures relevant to the manuscript.